Drug intelligence / Profile preview

lactobacillus rhamnosus LBV96

Development stage: Preclinical
Lead developer: Chr. Hansen
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

*Lactobacillus rhamnosus* LBV96 is a specific probiotic bacterial strain utilized for its ability to colonize and support the female reproductive tract's microbiome. It is frequently administered as part of a multi-strain probiotic formulation, such as OMNi-BiOTiC FLORA plus +, which also includes *L. crispatus* LBV88, *L. jensenii* LBV116, and *L. gasseri* LBV150N. The strain is primarily investigated for its role in restoring a healthy vaginal microbiota, particularly in women undergoing fertility treatments like in-vitro fertilization (IVF) or those at risk for gestational diabetes mellitus. By promoting a Lactobacillus-dominant environment, it helps prevent dysbiosis and may improve reproductive outcomes and metabolic health during pregnancy.

Brand names: OMNi-BiOTiC FLORA plus +
Other names: Lactobacillus rhamnosus LBV96

Beyond the preview

Go deeper on lactobacillus rhamnosus LBV96.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus rhamnosus LBV96.

Explore the full profile